octanate, 50 iu/ml powder and solvent for solution for injection
octapharma (ip) limited - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu/ml - antihemorrhagics
haemoctin sdh 500
biotest pharma gmbh landsteinerstrasse 5, 63303 dreieich, germany - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu/ml - antihemorrhagics
replenine-vf 50 iu/ml powder and solvent for solution for injection
bpl bioproducts laboratory gmbh dornhofstraße 34, 63263 neu-isenburg,, germany - factor ix, human - powder for solution for injection - factor ix, human 50 iu/ml - antihemorrhagics
koate dvi 250
padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.
csl bulk human coagulation factor viii 500 iu (50 iu/ml) / von willebrand factor 1200 iu powder for injection vial
csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, powder for - excipient ingredients: sodium citrate dihydrate; trometamol; calcium chloride dihydrate; albumin; sucrose; sodium chloride - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.
csl hong kong aleviate human coagulation factor viii 250iu/von willebrand factor 500iu complex, powder for injection (50 iu/ml fviii)
csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - aleviate is indicated for: ? the treatment of bleeding episodes including surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. ? the treatment and prophylaxis of bleeding associated with factor fviii deficiency due to haemophilia a.
biostate human coagulation factor viii 500iu / von willebrand factor 1200iu powder for injection vial with diluent vial
csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.
octanate 100iu/ml powder and solvent for solution for injection
octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - factor viii, human - powder and solvent for solution for injection - factor viii, human 100 iu/ml - antihemorrhagics
hemofil m antihemophillic factor (human) method m monoclonal purified
takeda israel ltd - factor viii (human) - powder for solution for injection - factor viii (human) 220 - 2000 iu/vial - coagulation factor viii - coagulation factor viii - hemophilia a - for the prevention and control of hemorrhagic episodes
koate dvi 500
padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.